Showing results (61-70 of 128) with videos related to

Sort By:
Pageof 13
Nature Communications|July 29, 2026
A distinct CAR-T cell phenotype mediates therapeutic response at limited dosesSchayan Yousefian, Maria-Luisa Schubert, Anna Rita Minafra, et al.
NPJ Precision Oncology|December 15, 2025
Benchmarking progression-free survival ratio as primary endpoint in precision oncology clinical trialsFederico Nichetti, Jennifer Hüllein, Pauline du Rusquec, et al.
Nature Communications|December 19, 2020
Glioblastoma epigenome profiling identifies SOX10 as a master regulator of molecular tumour subtypeYonghe Wu, Michael Fletcher, Zuguang Gu, et al.
Nature Cancer|February 5, 2022
TNF-α-producing macrophages determine subtype identity and prognosis via AP1 enhancer reprogramming in pancreatic cancerMengyu Tu, Lukas Klein, Elisa Espinet, et al.
Cancer Treatment and Research Communications|September 11, 2025
Rationale and design of the PAMSARC (pasireotide as maintenance treatment with monthly deep intramuscular injection in SSTR2/3/5-expressing synovial sarcoma and desmoplastic small round cell tumor) multicenter phase 2 trialChristoph E Heilig, Christoph Heining, Editha Gnutzmann, et al.
Infection, Genetics and Evolution : Journal of Molecular Epidemiology and Evolutionary Genetics in Infectious Diseases|February 25, 2024
Evolution of SARS-CoV-2 in the Rhine-Neckar/Heidelberg Region 01/2021 - 07/2023Christian Bundschuh, Niklas Weidner, Julian Klein, et al.
Cold Spring Harbor Molecular Case Studies|December 1, 2016
Integration of genomics and histology revises diagnosis and enables effective therapy of refractory cancer of unknown primary with PDL1 amplificationStefan Gröschel, Martin Bommer, Barbara Hutter, et al.
Nature Genetics|December 9, 2014
BAZ2A (TIP5) is involved in epigenetic alterations in prostate cancer and its overexpression predicts disease recurrenceLei Gu, Sandra C Frommel, Christopher C Oakes, et al.
Blood|December 21, 2018
The mutational landscape of Burkitt-like lymphoma with 11q aberration is distinct from that of Burkitt lymphomaRabea Wagener, Julian Seufert, Francesco Raimondi, et al.
Cold Spring Harbor Molecular Case Studies|March 6, 2019
Response to olaparib in a PALB2 germline mutated prostate cancer and genetic events associated with resistancePeter Horak, Joachim Weischenfeldt, Gunhild von Amsberg, et al.
Pageof 13